SPONSOR
The First Affiliated Hospital of Xiamen University
Total Trials
17
Recruiting
17
Phases
Phase 4, EARLY_Phase 1, Phase 2
Conditions studied: Type 2 Diabetes PatientsOverweight and ObesityHyperglycaemia (Diabetic)AF - Atrial FibrillationHTN-HypertensionDry Eye DiseaseUmbilical Cord Mesenchymal Stem Cell-derived Small Extracellular VesiclesMultiple MyelomaRelapsed/RefractoryBreast Cancer
The First Affiliated Hospital of Xiamen University is a clinical research sponsor with 17 registered studies on ClinicalTrials.gov, of which 17 are actively recruiting participants. Research covers conditions including Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic), AF - Atrial Fibrillation.
The trial portfolio spans Phase 4, EARLY_Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — The First Affiliated Hospital of Xiamen University
How many clinical trials has The First Affiliated Hospital of Xiamen University sponsored?
ClinicalMetric currently tracks 17 clinical trials sponsored by The First Affiliated Hospital of Xiamen University, of which 17 are actively recruiting participants. These trials cover conditions including Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does The First Affiliated Hospital of Xiamen University research focus on?
The First Affiliated Hospital of Xiamen University clinical trials span Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic), AF - Atrial Fibrillation, HTN-Hypertension, and additional conditions. The research pipeline includes Phase 4, EARLY_Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a The First Affiliated Hospital of Xiamen University clinical trial?
To participate in a The First Affiliated Hospital of Xiamen University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all The First Affiliated Hospital of Xiamen University trials with current recruitment status updated daily.
Clinical Trials by The First Affiliated Hospital of Xiamen University
NCT03087032 Phase 4
Recruiting
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
Type 2 Diabetes Patients
NCT05841615
Recruiting
Pulmonary Vein Isolation (PVI) Combined With Renal Denervation (RDN) in Atrial Fibrillation (AF) and Hypertension (HTN)
AF - Atrial Fibrillation
NCT07623382 EARLY_Phase 1
Recruiting
Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease
Dry Eye Disease
NCT06581640 Phase 2
Recruiting
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
NCT07046689
Recruiting
PET/CT for Trop2 ADC Response Evaluation Cancers
Breast Cancer
NCT07547930 Phase 2
Recruiting
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Thyroid Eye Disease, TED
NCT07035938
Recruiting
T-cell Developmental Status in Patients With Malignant Hematological Tumors
Hematologic Malignancy
NCT06757023
Recruiting
A Clinical Follow-up Study on the Efficacy of Thumbtack Needle for Postoperative Sleep and Recovery Treatment
Postoperative Complications
NCT05970666 Phase 2
Recruiting
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Adebrelimab
NCT06151080 Phase 2
Recruiting
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
DLBCL - Diffuse Large B Cell Lymphoma
NCT05603884 Phase 2
Recruiting
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
NCT06826118 Phase 2
Recruiting
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
Lymphoma
NCT07778212
Recruiting
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
DLBCL - Diffuse Large B Cell Lymphoma
NCT07883070
Recruiting
Study of Anxiety and Depression in Patients With Hematologic Malignancies
Hematologic Disease
NCT06651853 Phase 2
Recruiting
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Diffuse Large B-cell Lymphoma
NCT07749365 Phase 2
Recruiting
Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
DLBCL - Diffuse Large B Cell Lymphoma
NCT07885436
Recruiting
68Ga-XHER2 PET/CT for HER2 Assessment
Solid Tumor (Excluding CNS)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology